Samuel J. Reich, Executive Chairman at SAB Biotherapeutics, Inc. (SABS), bought 11,000 shares at $0.89 ($10K) on 2023-11-29, disclosed to the SEC on 2023-11-30.
Open-market purchase of $10k SABS by Executive Chairman. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |